MetLife Investment Management’s Crescent Biopharma CBIO Stock Holding History

MetLife Investment Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-166	Closed	-$198K	–	2356
2019 Q2	$198K	Hold	166	–	–	﹤0.01%	2027
2019 Q1	$207K	Hold	166	–	–	﹤0.01%	1965
2018 Q4	$158K	Hold	166	–	–	﹤0.01%	2043
2018 Q3	$240K	Hold	166	–	–	﹤0.01%	1982
2018 Q2	$268K	Buy	+166	New	+$285K	﹤0.01%	1771

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

MetLife Investment Management's CBIO Position: Q3 2019 in Review

MetLife Investment Management sold out of Crescent Biopharma (CBIO) in Q3 2019, closing a stake of 166 shares — an estimated $198K sold.

MetLife Investment Management first reported a position in CBIO in Q2 2018 and held it in 5 quarters. The position peaked at $268K in Q2 2018. 75 funds tracked by Wall St. Rank hold CBIO as of Q3 2019.

MetLife Investment Management reported no remaining Crescent Biopharma position as of Q3 2019 after selling out during the quarter.
MetLife Investment Management sold 166 Crescent Biopharma shares in Q3 2019, an estimated $198K.
MetLife Investment Management first reported a position in Crescent Biopharma in Q2 2018 and held it in 5 quarters.
MetLife Investment Management's Crescent Biopharma position peaked at $268K in Q2 2018.
75 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2019.

Based on MetLife Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.